매출 하락 → 마진 압박 → 현금 악화
Critical매출이 -1.0% 감소하며 영업이익률이 11.8%에서 9.2%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.
Evidence
매출 YoY -1.0% (2023→2024)영업이익률 11.8%→9.2%영업CF 14,366→13,158
Daejung Chemicals & Metals
A120240 · KOSDAQ₩14,320+1.56%
2026-08-03 closeDaejung Chemicals & Metals — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
CloseMA20MA60MA120
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Why this signalSignal guide
Moving-average alignment
Yes · score 0.23
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock flashed this signal 2 times over the last ~2 years (see the signal history below for each date).
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 110 화학 peers · not investment advice
Valuation in its own history
PER 10.64 · PBR 0.6 — own history (2010-12~) percentiles 48/100 · 94/100
PER48/100
PBR94/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 11 consecutive years · Raised 0 consecutive years · Yield 2.93% (based on 2025 payment of 420원) · 3-year growth +11.9%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 10.48
Distress
Grey
Safe
- Altman Z''
- 10.48
- Beneish M-Score
- -2.62
- Sloan accrual
- -1.72%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
6/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score6/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROANot passed
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
KRAs of 2026-08-03화학
This stock is in 화학: revenue rank 73 of 109, share 0.1%.
73 / 1090.1%revenue share
Who dominates this industry?
- 1LG화학31.9%
- 2롯데케미칼13.3%
- 3금호석유화학4.7%
- 4DL3.7%
- 5코오롱인더3.2%
- 6대정화금0.1%
Concentration
DistributedCR3 49.9%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
MixedConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 8.66
- Direction
- 확대
- Level
- 보통
- Years
- 6
Value lens
- P90/P10
- 9.3
- Median P/B
- 0.71
- Level
- 넓음
- n
- 98
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 9.2%
- Interest coverage
- 31.8x
- Return on equity (ROE)
- 5.6%
Operating margin −5pp
Severe margin pressureInterest coverageBase 31.8x adverse case 14.5x
Return on equity (ROE)Base 5.6% adverse case 2.1%
Revenue −15%
TolerableInterest coverageBase 31.8x adverse case 27x
Return on equity (ROE)Base 5.6% adverse case 4%
Interest rate +2pp
TolerableInterest coverageBase 31.8x adverse case 10x
Return on equity (ROE)Base 5.6% adverse case 4.4%
Interest coverage limit
Current margin 8.9ppInterest coverage limit at an operating margin of 0.3%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
Financials at a glance
Daejung Chemicals & Metals's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 송기섭51.36%2025-07-01 · 증감 -0.66%p
- 삼전순약공업5.74%2026-06-26 · 증감 +5.74%p
Connections
AI-extracted related companies · for reference
Customers
삼성바이오로직스Price comovement r=0.17 (1 year)셀트리온Price comovement r=0.28 (1 year)SK바이오사이언스Price comovement r=0.34 (1 year)종근당Price comovement r=0.32 (1 year)한미약품Price comovement r=0.23 (1 year)대웅제약Price comovement r=0.25 (1 year)삼성바이오에피스유한양행Price comovement r=0.28 (1 year)대원제약Price comovement r=0.42 (1 year)노바티스화이자테바머크
Competitors
Recent filings
Daejung Chemicals & Metals's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
Strong buy (52w high + volume)×2
26-07-21·26-07-16·
52-week high breakout×5
26-07-27·26-07-24·26-07-23·26-07-22·26-07-21·
Golden cross×1
26-04-01+1.4%
New MA alignment×6
26-08-03·26-07-20·26-04-24-1.4%26-04-10-7.3%26-04-08-4.8%26-04-03-3.5%
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy